References
- M. Engl. J. Med. v.313 Observations on the systemic administraion of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer Rosenberg, S.;M. Lotze;L. Muul;S. Leitman;A. Chang;S. Ettinghausen;Y. Matury;J. Skibber;E. Shilon;J. Vetto;C. Seipp;C.Smpson;C. Reichert
- J. Immunol. v.135 The antitumor efficacy of lymphokine-actovated killer cells and recombinant interleukin-2 in vivo Mule, J.J.;S. Shu, S.Rosenberg
- J. Immunol. v.138 Long-term growth of lymphokine-activated killer (LAK) cells : role of anti-CD3, β-IL-1, interferon-γ and β Ochoa, A.C.;G. Gromo;B.J. Alter;P.M. Sondel;F.Ⅱ. Bach
- J. Immunol. v.138 Lymphokine-activated killer (LAK). Ⅱ. Delineation of distinct murine LAK-precursor subpopulation Ballas, Z.K.;W.Rasmussen;J.K. Van Otegham
- J. Immunol. v.137 Murine lymphokine-activated killer (LAK) cells:phenoytpic characterization of the precursors and effector cells Tang, J.C.;J.J. Mule;S. Rosenberg
- J. Exp. Med. v.155 Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes Geimm, E.A.;A. Mazumder, Ⅱ;Z. Zhang;S.A. Rosenberg
- J. Biol. Resp. Mod. v.1 Biological Response Modifiers Program Oldham, R.K.
- Behring Inst. Mitt. v.74 Tumor models to investigate the therapeutic efficiency of immunomodulators Talmadge, E.;Lenz, B.F.;Collins, M.S.;Uithoven, K.A.;Schneider, M.A.;Adam-s, J.S.;Pearson, J.W.;Agee, W.J.;Fox, R.E.;Oldham, R.K.
- Behring Inst, Mitt. v.74 The NCI preclinical screen of biolog-ical response modifiers Talmadge, J.E.;Fidler, I.J.;Oldham, R.K.
- Phytochemistry v.11 Immunologically active polysaccharide-s of A-contopanax senticosus Fang, J.N.;Proksch, A.;Wagner, H.
- Drug Exptl. Clin. Res. v.12 Phase Ⅰ trials of biological response modifiers Smalley, R.V.;Oldham, R.K.
- Cancer Treatment Resports v.70 The preclinical screening laboratory: Eval-uation of immunomodulatory and therapeutic properties of biological response modifiers Talmadge, J.E.;Herberman, R.B.
- J. Immunology v.134 Augmentation of mouse natural killer cell activity by LS 2616: a new immunomodulator Kalland, T.;Alm, G.;Stalhandske, T.
- Mol. Biother. v.1 The ideal biological response modifier Wimer, B.M.
- Jpn. J. Cancer Res. v.70 Comparative study on antitumor effect of cell-wall skeleton of Mycovacterium bovis BCG and Nocardia rubra. with reference to T-cell dependency and independency Yanagawa, E.;Yasumoto, K.;Ohta, M;Nomoto, K.;Azuma, I.;Yamamura, Y.
- Int. J. Immunopharmac. v.3 In Vitro augmentation of natural killing activity by OK-432 Atsushi Uchida, Michael Micksche
- Cancer v.66 Evaluation of the worth of Corynebacterium parvum in conjuction with chemotherpy as adjuvant treatment for primary breast cancer Fisher, B.;Brown, A.;Wolmark, N.;Fisher, E.R.;Redmond, C.;Wickerham, D.L.;Margolese R.;Dimitrov. N. Pilch Y.;Glass A.;Sutherland C.;Foster R.
- Proc. Natl. Acad. Sci. v.85 Induction of macrophage antitumor activity by a cetylated low density lipoprotein containing lipophilic tripeptide Shaw, J.M.;Futch, W.S.;Schook, L.B.
- Nature v.232 Endotoxin and double-stranded RNA render macrophages cytotoxic Alexander, P.;Evans, R.
- Nature v.330 A new immunomodulating compound (AS101) with potential therapeutic application B. Sredri;R.R. Caspi;A. Klein;Y. Kalechman;Y. Danziger;M. BenYa'akov;T. Tamari;F. Shalit;M. Albeck
- In progres-s in cancer research and therpy v.20 Lymphokines and thymic hormones Goldstein, A.L.;Ahirigos, M.A.
- Intl. J. Immunopharmacol. v.6 T-cell mediated vascular dilation and genorrhage induced by antitumor polysaccharide Maeda, Y.Y.;Watanabe, S.T.Chihara, G.;Rokutanda, M.
- J. Natl. Med. Assoc. v.81 a new antineoplastic immunomodula-tor Mohla, S.;Humphries M.J.;White, S.L.;Matsumoto, K.;Newton, S.A.;Sampson, C.C.;Bowen, D.;Olden, K.;Swansonine
- J. Natl. Cancer Institute v.80 Natural products as antitumor agents:direct versus indirect mechanisms of activity of flavonoids Robert H. Wiltrout;Ronald L. Hornung
- Prog. Med. Virol. v.18 On the role of mononuclear phagocytes in immunity Allison, A.C.
- Bact. Rev. v.28 Aspects of the pathogenesis of virus diseases Mims, C.A.
- Microbiolol. Rev. v.43 Role of macrophage in natural resistance to virus infections Mogensen, S.C.
- J. Infect. Dis. v.135 Therapeutic efficacy of liposome-encapsulated robavirin and muramyl tripeptide in experimental infection with influenza and herpes simplex virus Gangemi D.;Nachtigal M.;Barnhart D.;Krech L.;Jani P.J.
- J. Infect. Dis. v.135 Immunonodulation of host resistance to experimental viral infections in mice Glasgow, L.A.;Fischbach, J.;Bryant, S.M.;Kern, E.R.
- Infect. Immun. v.16 Protection against herpes simplex infection in mice by Corynevacterium parvum Kirchner, H.;Hirt, H.M.;Munk, K.
- Ann. Rev. Microbiol. v.43 The genomes of the human herpesviruses: Contents, relationship-s and evolution McGeoch, D.J.
- Proc. Soc. Exp. Biol. Med. v.154 Immunomodulator-induced resista-nce against herpes simplex virus Morahan, P.S.;Kern, E.R.;Glasgow, L.A.
- Nature v.268 Macrophages isolated from regression: Molon-ey sarcoma are more cytotoxic than those recovered from progressing sarcomas Russell, S.W.;McIntosh, A.T.
- Cell. Immunol. v.53 The murine bone marrow macrophage. a sensitive indicator cell for murine inhibitory factor and a new method for their harvest Klimetzek, V.;Remold, H.G.
- J. Leukoc. Biol. v.50 Poly Ⅰ:C-induced anti-herp-es simplex virus type Ⅰ activity in inflammatory macrophages is mediated by induction of interferon-β Pyo, S.;Gangmi, J.D.;Ghaffar A.;Mayer E.P.